{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Bone&page=94",
    "query": {
      "condition": "Cancer Bone",
      "page": 94
    },
    "page_size": 10
  },
  "pagination": {
    "page": 94,
    "page_size": 10,
    "total_count": 3411,
    "total_pages": 342,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Bone&page=95&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Bone&page=93&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T20:55:30.859Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04049539",
      "title": "Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Blasts More Than 5 Percent of Bone Marrow Nucleated Cells",
        "Persistent Disease",
        "Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Liposome-encapsulated Daunorubicin-Cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 28,
      "start_date": "2021-01-29",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-11-17T20:55:30.859Z",
      "location_count": 2,
      "location_summary": "Sacramento, California • Columbus, Ohio",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04049539"
    },
    {
      "nct_id": "NCT06594445",
      "title": "HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myeloid Malignancy",
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "GTB-360",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2024-11-19",
      "completion_date": "2027-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-11-17T20:55:30.859Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06594445"
    },
    {
      "nct_id": "NCT00005795",
      "title": "Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "arsenic trioxide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2000-02",
      "completion_date": "2002-07",
      "has_results": false,
      "last_update_posted_date": "2012-06-11",
      "last_synced_at": "2026-11-17T20:55:30.859Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005795"
    },
    {
      "nct_id": "NCT05444530",
      "title": "A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "VAC85135",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2022-07-21",
      "completion_date": "2025-06-24",
      "has_results": false,
      "last_update_posted_date": "2025-07-20",
      "last_synced_at": "2026-11-17T20:55:30.859Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Tampa, Florida • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05444530"
    },
    {
      "nct_id": "NCT07477457",
      "title": "A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteosarcoma",
        "Metastasis"
      ],
      "interventions": [
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gefitinib",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        },
        {
          "name": "Disulfiram",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "6 Years to 49 Years"
      },
      "enrollment_count": 45,
      "start_date": "2026-03-11",
      "completion_date": "2028-03-11",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-11-17T20:55:30.859Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07477457"
    },
    {
      "nct_id": "NCT07349134",
      "title": "WELL-MPN: A Digital Lifestyle App for Patients With MPNs",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Myeloproliferative Neoplasms (MPNs)"
      ],
      "interventions": [
        {
          "name": "WELL-MPN Digital App",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2027-01",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-11-17T20:55:30.859Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07349134"
    },
    {
      "nct_id": "NCT00015847",
      "title": "Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 25,
      "start_date": "2001-04",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2025-08-22",
      "last_synced_at": "2026-11-17T20:55:30.859Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Portland, Oregon",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00015847"
    },
    {
      "nct_id": "NCT07019155",
      "title": "Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Germline Mutation",
        "Myelodysplastic Syndromes",
        "Acute Myeloid Leukemia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "1 Month to 120 Years"
      },
      "enrollment_count": 510,
      "start_date": "2025-07-24",
      "completion_date": "2035-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-11-17T20:55:30.859Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07019155"
    },
    {
      "nct_id": "NCT02259348",
      "title": "Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia (ALL)",
        "Acute Myeloid Leukemia (AML)",
        "Myeloid Sarcoma",
        "Chronic Myelogenous Leukemia (CML)",
        "Juvenile Myelomonocytic Leukemia (JMML)",
        "Myelodysplastic Syndrome (MDS)",
        "Non-Hodgkin Lymphoma (NHL)"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Interleukin-2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Natural killer cell therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "T-cell depleted HPC transplant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CD45RA-depleted HPC transplant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 12,
      "start_date": "2014-10",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-11-17T20:55:30.859Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02259348"
    },
    {
      "nct_id": "NCT03175978",
      "title": "IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndromes",
        "Leukemia, Myelomonocytic, Chronic",
        "Anemia, Refractory, With Excess of Blasts"
      ],
      "interventions": [
        {
          "name": "IGF/MTX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IGF Oncology, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2018-02-21",
      "completion_date": "2021-09-30",
      "has_results": true,
      "last_update_posted_date": "2024-05-21",
      "last_synced_at": "2026-11-17T20:55:30.859Z",
      "location_count": 2,
      "location_summary": "Rochester, Minnesota • Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03175978"
    }
  ]
}